Bioxcel therapeutics appoints matt wiley chief commercial officer

New haven, conn., jan. 19, 2022 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of matt wiley as senior vice president and chief commercial officer (cco).
BTAI Ratings Summary
BTAI Quant Ranking